Literature DB >> 2476360

Rat but not human interferons suppress hepatic oxidative drug metabolism in rats.

P I Craig1, S J Williams, E Cantrill, G C Farrell.   

Abstract

An animal model suitable for in vivo studies of interferon-mediated suppression of hepatic oxidative drug metabolism has been developed. Rats were injected with either recombinant human interferon alpha A, recombinant human interferon gamma, recombinant rat interferon gamma, or vehicle and experiments were performed 24 h later. In some animals theophylline elimination was determined twice (10 days apart), once after interferon and once after vehicle. Theophylline clearance was also determined in the isolated perfused rat liver after pretreatment of animals with interferon or vehicle. Pretreatment of animals with rat interferon gamma significantly reduced theophylline clearance in the intact rat but neither human interferon alpha A nor human interferon gamma altered theophylline elimination in vivo. Similar results were observed in the isolated perfused rat liver. We then examined whether the effects of interferon on hepatic drug metabolism were generalized or confined to individual cytochrome P450 isozymes; androstenedione hydroxylation pathways were used as catalytic probes for individual cytochrome P450 isozymes. Rat interferon gamma (but not human interferon alpha A) decreased levels of total hepatic microsomal P450 and reduced androstenedione 16 beta-hydroxylation. The formation of three other hydroxylated androstenedione metabolites appeared reduced to a similar extent, although these changes were not significant. It is concluded that autologous but not heterologous interferons impair oxidative drug metabolism in the rat. The reduction of hepatic P450 produced by interferon may result from the suppression of multiple isozymes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476360     DOI: 10.1016/0016-5085(89)91509-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  5 in total

1.  Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha.

Authors:  Makrem Ben Reguiga; Laurence Bonhomme-Faivre; Simone Orbach-Arbouys; Robert Farinotti
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

2.  Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients.

Authors:  B C Israel; R A Blouin; W McIntyre; S I Shedlofsky
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

Review 3.  Pharmacokinetic alterations after severe head injury. Clinical relevance.

Authors:  B A Boucher; S D Hanes
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

Review 4.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

5.  Alpha interferon has no effect on lidocaine metabolism in the rat.

Authors:  E Melzer; E Bardan; I Ronen; Z Krepel; S Bar Meir
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Apr-Jun       Impact factor: 2.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.